Evidence mapPaperPMID 31350593Full record

ReviewCurrent atherosclerosis reports2019

Subclinical Cerebrovascular Disease: Epidemiology and Treatment.

Adam de Havenon, Chelsea Meyer, J Scott McNally, Matthew Alexander, Lee Chung

Open access · greenAbstract readReview
In one paragraph

Review in Current atherosclerosis reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Subclinical cardiac dysfunction and circulating markers of brain injury in older adults: The cardiovascular health study.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2025
    Article
  6. The role of T cells in vascular aging, hypertension, and atherosclerosis.American journal of physiology. Heart and circulatory physiology · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Adam de HavenonDepartment of Neurology, University of Utah, Salt Lake City, UT, USA. adam.dehavenon@hsc.utah.edu.
Chelsea MeyerDepartment of Neurology, University of Utah, Salt Lake City, UT, USA.
J Scott McNallyDepartment of Radiology, University of Utah, Salt Lake City, UT, USA.
Matthew AlexanderDepartment of Radiology, University of Utah, Salt Lake City, UT, USA.
Lee ChungDepartment of Neurology, University of Utah, Salt Lake City, UT, USA.
University of Utah · US

Funding

Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRIK23NS105924 · NINDS · YALE UNIVERSITY · PI DE HAVENON, ADAM H. · 2019 to 2023
$988k
NINDS NIH HHS K23 NS105924
6 · The paper itself

Abstract

purpose of reviewSubclinical cerebrovascular disease (sCVD) is highly prevalent in older adults. The main neuroimaging findings of sCVD include white matter hyperintensities and silent brain infarcts on T2-weighted MRI and cerebral microbleeds on gradient echo or susceptibility-weighted MRI. In this paper, we will review the epidemiology of sCVD, the current evidence for best medical management, and future directions for sCVD research. RECENT

findingsNumerous epidemiologic studies show that sCVD, in particular WMH, is an important risk factor for the development of dementia, stroke, worse outcomes after stroke, gait instability, late-life depression, and death. Effective treatment of sCVD could have major consequences for the brain health of a substantial portion of older Americans. Despite the link between sCVD and many vascular risk factors, such as hypertension or hyperlipidemia, the optimal medical treatment of sCVD remains uncertain. Given the clinical equipoise about the risk versus benefit of aggressive medical management for sCVD, clinical trials to examine pragmatic, evidence-based approaches to management of sCVD are needed. Such a trial could provide much needed guidance on how to manage a common clinical scenario facing internists and neurologists in practice.

Indexed as

AgedAged, 80 and overAspirinAsymptomatic DiseasesBrain InfarctionDementiaFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukoaraiosisMagnetic Resonance ImagingMaleMiddle AgedPlatelet Aggregation InhibitorsPrevalenceRisk FactorsAspirinHydroxymethylglutaryl-CoA Reductase InhibitorsPlatelet Aggregation InhibitorsCerebral microbleedSilent cerebral infarctSubclinical cerebrovascular diseaseWhite matter hyperintensity

Identifiers

PMID31350593
PMCPMC8011954
OpenAlexW2964614037

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.